“ (Weight loss medications) can help, for sure, but exercise and getting enough protein to make sure you aren’t losing muscle ...

Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...

Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...

A weight-loss drug more effective than Ozempic and Wegovy has recently been approved. Here’s how it works and how it compares ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug ...

Goldman Sachs analyst Salveen Richter has reiterated their bullish stance on AMGN stock, giving a Buy rating yesterday. Salveen Richter has ...